Works matching IS 03125963 AND DT 2024 AND VI 63 AND IP 3

Results: 11

Toward Genetic Testing of Rivaroxaban? Insights from a Systematic Review on the Role of Genetic Polymorphism in Rivaroxaban Therapy.

Published in:

Clinical Pharmacokinetics, 2024, v. 63, n. 3, p. 279, doi. 10.1007/s40262-024-01358-3

By:

Ma, Yi;
Song, Zaiwei;
Li, Xinya;
Jiang, Dan;
Zhao, Rongsheng;
Yi, Zhanmiao

Publication type:

Article

Bayesian Vancomycin Model Selection for Therapeutic Drug Monitoring in Neonates.

Published in:

Clinical Pharmacokinetics, 2024, v. 63, n. 3, p. 367, doi. 10.1007/s40262-024-01353-8

By:

Alrahahleh, Dua'a;
Thoma, Yann;
Van Daele, Ruth;
Nguyen, Thi;
Halena, Stephanie;
Luig, Melissa;
Stocker, Sophie;
Kim, Hannah Yejin;
Alffenaar, Jan-Willem

Publication type:

Article

A Population Pharmacokinetic Analysis of l-Glutamine Exposure in Patients with Sickle Cell Disease: Evaluation of Dose and Food Effects.

Published in:

Clinical Pharmacokinetics, 2024, v. 63, n. 3, p. 357, doi. 10.1007/s40262-024-01349-4

By:

Sadaf, Alina;
Dong, Min;
Pfeiffer, Amanda;
Latham, Teresa;
Kalfa, Theodosia;
Vinks, Alexander A.;
Ware, Russell E.;
Quinn, Charles T.

Publication type:

Article

Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm.

Published in:

Clinical Pharmacokinetics, 2024, v. 63, n. 3, p. 381, doi. 10.1007/s40262-024-01347-6

By:

Huh, Yeamin;
Wojciechowski, Jessica;
Purohit, Vivek S.

Publication type:

Article

Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.

Published in:

Clinical Pharmacokinetics, 2024, v. 63, n. 3, p. 293, doi. 10.1007/s40262-023-01330-7

By:

Fan, Yuru;
Zhang, Xuan;
Zhang, Qin;
Zheng, Liang;
Zhou, Renpeng;
Sun, Cheng;
Wang, Xihan;
Song, Ke;
He, Zhusheng;
Wang, Honghui;
Zhang, Qian;
Hu, Wei

Publication type:

Article

Maternal Ezetimibe Concentrations Measured in Breast Milk and Its Use in Breastfeeding Infant Exposure Predictions.

Published in:

Clinical Pharmacokinetics, 2024, v. 63, n. 3, p. 317, doi. 10.1007/s40262-023-01345-0

By:

Yeung, Cindy H. T.;
Autmizguine, Julie;
Dalvi, Pooja;
Denoncourt, Audrey;
Ito, Shinya;
Katz, Pamela;
Rahman, Mehzabin;
Theoret, Yves;
Edginton, Andrea N.

Publication type:

Article

Comment on: Anti-Coagulant Treatment of Cancer-Associated Thrombosis in Frail Patients: Impact of Frailties on the Management of Drug–Drug Interactions.

Published in:

Clinical Pharmacokinetics, 2024, v. 63, n. 3, p. 395, doi. 10.1007/s40262-023-01344-1

By:

Van der Linden, Lorenz;
Vanassche, Thomas;
Van Aelst, Lucas;
Verhamme, Peter

Publication type:

Article

Lumacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients with Cystic Fibrosis: A First Step Toward Personalized Therapy.

Published in:

Clinical Pharmacokinetics, 2024, v. 63, n. 3, p. 333, doi. 10.1007/s40262-023-01342-3

By:

Bouazza, Naïm;
Urien, Saïk;
Foissac, Frantz;
Choupeaux, Laure;
Lui, Gabrielle;
Froelicher Bournaud, Léo;
Rouillon, Steeve;
Zheng, Yi;
Bardin, Emmanuelle;
Stremler, Nathalie;
Bessaci, Katia;
Bihouee, Tiphaine;
Coirier-Duet, Emmanuelle;
Marguet, Christophe;
Deneuville, Eric;
Laurans, Muriel;
Reix, Philippe;
Gerardin, Michèle;
Mittaine, Marie;
Epaud, Ralph

Publication type:

Article

Population Pharmacokinetic/Pharmacodynamic Models for P2Y12 Inhibitors: A Systematic Review and Clinical Appraisal Using Exposure Simulation.

Published in:

Clinical Pharmacokinetics, 2024, v. 63, n. 3, p. 303, doi. 10.1007/s40262-023-01335-2

By:

Chen, Jingcheng;
Qu, Yuchen;
Jiang, Muhan;
Li, Haiyan;
Cui, Cheng;
Liu, Dongyang

Publication type:

Article

Salivary Therapeutic Drug Monitoring of Antimicrobial Therapy: Feasible or Futile?

Published in:

Clinical Pharmacokinetics, 2024, v. 63, n. 3, p. 269, doi. 10.1007/s40262-024-01346-7

By:

Davies Forsman, Lina;
Kim, Hannah Yejin;
Nguyen, Thi Anh;
Alffenaar, Jan-Willem C.

Publication type:

Article

Towards More Robust Evaluation of the Predictive Performance of Physiologically Based Pharmacokinetic Models: Using Confidence Intervals to Support Use of Model-Informed Dosing in Clinical Care.

Published in:

Clinical Pharmacokinetics, 2024, v. 63, n. 3, p. 343, doi. 10.1007/s40262-023-01326-3

By:

van Borselen, Marjolein D.;
Sluijterman, Laurens Auke Æmiel;
Greupink, Rick;
de Wildt, Saskia N.

Publication type:

Article